news flash·2025-06-30 03:24Core Viewpoint - The report from Industrial Securities highlights that China's innovative drugs possess high efficiency and low-cost development advantages, particularly in popular technology areas such as ADC, bispecific antibodies, and cell therapy, indicating a competitive edge in the industry [1] Group 1: Stock Performance - Zhaoyan New Drug reached the daily limit increase, while Tigermed, Haoyuan Medicine, and Kylin Pharmaceutical rose over 5% [1] - Other companies such as Jinkai Biotechnology, WuXi AppTec, Sunshine Nuohe, and Kanglong Chemical also experienced upward movement in their stock prices [1] Group 2: Industry Insights - The report emphasizes that the current competitive advantages in the innovative drug sector are expected to continue showcasing industry competitiveness [1]